- BI-ARYL DIHYDROOROTATE DEHYDROGENASE INHIBITORS
-
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3, and Q are defined herein.
- -
-
Page/Page column 324-325
(2021/04/17)
-
- BENZOFURAN AND BENZOPYRAN DIHYDROOROTATE DEHYDROGENASE INHIBITORS
-
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows, wherein R1, R2, R3 and A are defined herein.
- -
-
Page/Page column 60
(2021/12/08)
-
- NOVEL 3,4-DISUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINES AND 4,5-DISUBSTITUTED-7H-PYRROLO[2,3-C]PYRIDAZINES AS LRRK2 INHIBITORS
-
The present invention provides novel 3,4-disubstituted-1 H-pyrrolo[2,3- Jb]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof (I) wherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.
- -
-
Page/Page column 52; 53
(2015/07/07)
-
- IMIDAZOLE DERIVATIVES
-
The present invention relates to compounds of formula (I), wherein A, B, R1 and R2 are as defined herein before.
- -
-
Page/Page column 21; 22
(2015/06/11)
-
- HETEROAROMATIC PHENYLIMIDAZOLE DERIVATIVES AS PDE10A ENZYME INHIBITORS
-
This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The pr
- -
-
Page/Page column 42-43
(2011/07/07)
-
- HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
-
Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes
- -
-
Page/Page column 104
(2011/12/14)
-
- HAFNIUM COMPLEXES OF HETEROCYCLIC ORGANIC LIGANDS
-
Hafnium complexes of heterocyclic organic ligands having improved solubility in aliphatic hydrocarbon solvents and their use as components of olefin polymerization catalysts as well as novel syntheses of component parts thereof are disclosed.
- -
-
Page/Page column 17
(2009/04/24)
-